• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
TAL
Click for more information
12.5% 0.7¢

TALIUS GROUP LIMITED - News & Media

Market Cap $18.02M  ! watchlist Created with Sketch. Add to my watchlist
Technology Software - Application

Talius Group Limited provides a suite of technology enabled care solutions to the aged... Talius Group Limited provides a suite of technology enabled care solutions to the aged and disability sectors across multiple verticals, including retirement living, residential aged care, home, and community settings to improve the quality of life, later in life. The Company’s software as a service (SaaS) data analytics platform, Talius Smart Care, combines smart sensors with artificial intelligence (AI) machine learning that delivers automated actions. Its customized AI analysis uses predicative interpretation and monitors a range of indicators such as sleep, vital signs, falls, activities of daily living and social interaction. It links awareness, analysis, and action through one platform, allowing the care model to move from spot check care to sense-respond care. It helps protect and connect its elderly and people with disabilities with a scalable healthcare technology platform integrated with third-party providers to ensure end-to-end solutions for Connected Health.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No News & Media currently available.

(20min delay)
Last
0.7¢ 		Change
-0.001(12.5%) 		Mkt cap ! $18.02M
Open High Low Value Volume
0.7¢ 0.7¢ 0.7¢ $193 27.5K

Buyers (Bids)

No. Vol. Price($)
3 1180012 0.7¢
 

Sellers (Offers)

Price($) Vol. No.
0.8¢ 3669993 6
View Market Depth
Last trade - 11.41am 02/10/2024 (20 minute delay) ?
TAL (ASX) Chart

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
SPC to merge with Original Juice Co and Nature One Dairy The Original Juice Co Ltd has set up a transaction which will see it merge with Aussie icon SPC Global and Singapore-based Nature One Dairy
Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one Cobalt Blue has released estimates for what it would take to get its proposed Kwinana refinery off the ground, seeing CapEx of $60M.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.